Evidence map›Paper›PMID 41777650›Full record

ArticleFrontiers in oncology2026

Pilot study: predicting the interplay between FOXO1 and its downstream long non-coding RNAs in HCC.

Rowan Abdelbary, Sherine K Saber, Fabian Rose, Kai Breuhahn, Shereen A El Sobky, Injie Omar Fawzy, Ahmed Moustafa, Nada El-Ekiaby, Ahmed Ihab Abdelaziz

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Rowan AbdelbaryBiotechnology Graduate Program, American University in Cairo, Cairo, Egypt.
Sherine K SaberBiotechnology Graduate Program, American University in Cairo, Cairo, Egypt.
Fabian RoseInstitute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Kai BreuhahnInstitute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Shereen A El SobkySchool of Medicine, Newgiza University (NGU), Giza, Egypt.
Injie Omar FawzySchool of Medicine, Newgiza University (NGU), Giza, Egypt.
Ahmed MoustafaBiotechnology Graduate Program, American University in Cairo, Cairo, Egypt.
Nada El-Ekiaby *School of Medicine, Newgiza University (NGU), Giza, Egypt.
Ahmed Ihab Abdelaziz *School of Medicine, Newgiza University (NGU), Giza, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Methods: This was achieved through the analysis of publicly available ChIP-Seq data provided by ENCODE database, along with performing RNA sequencing after the knockdown of FOXO1 in Huh-7 cells. Results: ChIP-Seq data analyses revealed a list of 982 promising lncRNAs that are possibly regulated by FOXO1. Analysis of the RNA sequencing data revealed 131 lncRNAs that were differentially expressed after FOXO1 knockdown. The intersection between ChIP-Seq data and RNA sequencing data showed an overall of 12 lncRNAs that were differentially expressed upon FOXO1 knockdown and also have a FOXO1 binding site in their promoter region, namely Discussion: In conclusion, 12 lncRNAs were identified as potential downstream targets of FOXO1, suggesting that those lncRNAs could mediate FOXO1 functions in HCC.

Indexed as

ChIP-seqforkhead box O-1 (FOXO1)hepatocellular carcinomalong non-coding RNARNA sequencing

Identifiers

PMID41777650
PMCPMC12950588

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.